Business
First Day of Dealings on AIM
EDX Medical Group PLC has announced the admission of its ordinary shares to trading on the AIM Market of the London Stock Exchange, with dealings commencing today under the TIDM "EDX". Concurrently, the company's shares are being withdrawn from the Apex Segment of the Aquis Stock Exchange Growth Market. EDX Medical develops innovative digital diagnostic products and services for cancer and infectious diseases, aiming to compete in the £10 billion+ clinical diagnostics market in the UK and Europe. The company has established early revenues through distribution partnerships and a strong product pipeline via collaboration with Thermo Fisher, leveraging intellectual property from Oxford and Cambridge Universities. They are also developing a pioneering multiplex 'point of care' test platform for sepsis and prostate cancers. Disclaimer*
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\n\n \n13 May 2026\nEDX Medical Group PLC\n(\"EDX Medical\" or the \"Company\")\nFirst Day of Dealings on AIM\nCAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, is pleased to announce that the admission of its ordinary shares of £0.01 each (\"Ordinary Shares\") to trading on the AIM Market (\"AIM\"), a market operated by the London Stock Exchange, will take place today (\"Admission\"). Dealings in the Ordinary Shares on AIM will commence at 8:00 a.m. today under the TIDM \"EDX\" and ISIN: GB00BNDMJS47.\nAdditionally, the Company's Ordinary Shares will be withdrawn from trading on the Apex Segment of the Aquis Stock Exchange Growth Market with effect from 8:00 a.m. today, in accordance with AQSE Rule 5.3.\nKey Investment Highlights\n· Commercially scalable clear growth strategy, with potential to compete successfully in the £10 billion+ clinical diagnostics market in UK and Europe.\n \n· Specialist business model based on proprietary products addressing major areas of significant global impact on health, particularly cancer and infectious diseases.\n \n· Building a portfolio of unique, 'best in class', validated diagnostic products and services for the identification of genetic risk, early disease detection and characterisation.\n \n· Early revenues and market access via exclusive distribution partnerships with Caris Life Sciences and with Curesponse Ltd.\n \n· Strong product pipeline via collaboration with Thermo Fisher based on in-licensed intellectual property from Oxford and Cambridge Universities and others.\n \n· Pioneering multiplex 'point of care' test platform, providing quantitative data on multiple biomarkers, with digital reporting via mobile device, for sepsis and prostate cancers in development.\n\nAbout EDX Medical\nEDX Medical develops, validates and commercialises innovative digital diagnostic products and services, generating valuable biological insights that enable cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases.\nBy translating clini...